UBS Group
PPH icon

UBS Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

UBS Group’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
+23,300
New +$2.48M ﹤0.01% 4798

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

UBS Group's PPH Position: Q1 2026 in Review

UBS Group reduced its VanEck Pharmaceutical ETF (PPH) stake by 49% in Q1 2026, selling an estimated $5.58M and leaving 54,964 shares worth $5.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3934.

UBS Group first reported a position in PPH in Q4 2014 and has held it in 46 quarters since. The position peaked at $38M in Q2 2022. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

  • UBS Group held 54,964 shares of VanEck Pharmaceutical ETF worth $5.71M as of Q1 2026.
  • UBS Group sold 52,415 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $5.58M.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3934 holding.
  • UBS Group first reported a position in VanEck Pharmaceutical ETF in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's VanEck Pharmaceutical ETF position peaked at $38M in Q2 2022.
  • 147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.